Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infarcted myocardium.

[1]  K. Huber,et al.  Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. , 2002, Cardiovascular research.

[2]  Arnold E. Postlethwaite,et al.  Infarct scar as living tissue , 2002, Basic Research in Cardiology.

[3]  P. Anversa,et al.  Myocyte renewal and ventricular remodelling , 2002, Nature.

[4]  M. Gassmann,et al.  HIF‐1 is expressed in normoxic tissue and displays an organ‐specific regulation under systemic hypoxia , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  H. Sinzinger,et al.  The isoprostane 8-epi-PGF2α is a valuable indicator of oxidative injury in human heart valves , 2001 .

[6]  Federica Limana,et al.  Mobilized bone marrow cells repair the infarcted heart, improving function and survival , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Thalhammer,et al.  Angiogenesis stimulation in explanted hearts from patients pre-treated with intravenous prostaglandin E(1). , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  Y. Ikeda,et al.  CD34 expression on long-term repopulating hematopoietic stem cells changes during developmental stages. , 2001, Blood.

[9]  K. Weber,et al.  Infarct scar: a dynamic tissue. , 2000, Cardiovascular research.

[10]  H. Sinzinger,et al.  Accumulation of oxidized LDL in human semilunar valves correlates with coronary atherosclerosis. , 2000, Cardiovascular research.

[11]  M. Daemen,et al.  The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. , 1999, Cardiovascular research.

[12]  H. Sinzinger,et al.  The isoprostane, 8-epi-PGF2 alpha, is accumulated in coronary arteries isolated from patients with coronary heart disease. , 1999, Cardiovascular research.

[13]  R. Bjercke,et al.  Bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor. , 1999, Circulation research.

[14]  E. Hartter,et al.  Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. , 1999, Japanese heart journal.

[15]  G. Laufer,et al.  Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  E. Hartter,et al.  Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  G. Laufer,et al.  Prostaglandin E1--bridge to cardiac transplantation. Technique, dosage, results. , 1997, European heart journal.

[18]  R. Virmani,et al.  Apoptosis in myocytes in end-stage heart failure. , 1996, The New England journal of medicine.

[19]  John Calvin Reed,et al.  Programmed myocyte cell death affects the viable myocardium after infarction in rats. , 1996, Experimental cell research.

[20]  O. Hudlická,et al.  Factors involved in capillary growth in the heart , 1995, Molecular and Cellular Biochemistry.

[21]  P. Armstrong,et al.  Remodeling and reparation of the cardiovascular system. , 1992, Journal of the American College of Cardiology.

[22]  C. Fletcher,et al.  QBEND/10, a new monoclonal antibody to endothelium: assessment of its diagnostic utility in paraffin sections , 1990, Histopathology.

[23]  K. Nakagawa,et al.  Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[24]  C A Beltrami,et al.  Structural basis of end-stage failure in ischemic cardiomyopathy in humans. , 1994, Circulation.